High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients

American Journal of Hematology

Volumn 91, Issue 8, 2016, Pages 755-762

  Guolo, Fabio ^a   Minetto, Paola ^a   Clavio, Marino ^a   Miglino, Maurizio ^a   Di Grazia, Carmen ^a   Ballerini, Filippo ^a   Pastori, Giordana ^a   Guardo, Daniela ^a   Colombo, Nicoletta ^a   Kunkl, Annalisa ^a   Fugazza, Giuseppina ^a   Rebesco, Barbara ^a   Sessarego, Mario ^a   Lemoli, Roberto Massimo ^a   Bacigalupo, Andrea ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; THIOTEPA;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 84978229861     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24391     Document Type: Article

References (46)

1. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012;30:3924–3931.
2. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: A meta-analysis of individual patient data from randomized controlled trials. Lancet Oncol 2014;15:986–996.
3. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML 12 trial. J Clin Oncol 2010;28:586–595.
4. Estey EH. Acute myeloid leukemia: 2013 Update on risk-stratification and management. Am J Hematol 2013;88:318–327.
5. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 2015;373:1136–1152.
6. Ballen KK, Koreth J, Chen YB, et al. Selection of optimal alternative graft source: Mismatched unrelated donor, umbilical cord blood, or haploidentical transplant. Blood 2012;119:1972–1980.
7. Frassoni F, Gualandi F, Podestà M, et al. Direct intra bone transplant of unrelated cord-blood cells in acute leukemia: A phase I/II study. Lancet Oncol 2008;9:831–839.
8. Raiola AM, Dominietto A, Di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014;20:1573–1579.
9. Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: A report from SWOG and MD Anderson. Leukemia 2014;28:289–292.
10. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010;363:2091–2101.
11. The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med 2013;368:2059–2074.
12. Döhner H, Estey EH, Amadori S, et al. European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
13. Mrózek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European Leukemia Net standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012;30:4515–4523.
14. Grimwade D, Hills RK Moorman AV. National Cancer Research Institute Adult Leukaemia Working Group, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;16:354–365.
15. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 1998;92:2322–2333.
16. Schlenk RF, Döhner K, Krauter J, et al. German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:909–918.
17. 2 in AML induction: Results from the UK NCRI AML17 trial in 1206 patients. Blood 2015;125:3878–3885.
18. The Aml Collaborative Group. A systematic collaborative overview of randomized trials comparing Idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukemia. Br J Haematol 1998;103:100–109.
19. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clinic Oncol 1993;11:116–124.
20. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996;81:513–520.
21. Clavio M, Gatto S, Beltrami G, et al. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukemia. Leukemia and Lymphoma 2001;40:305–313.
22. Clavio M, Gatto S, Beltrami G, et al. Fludarabine, ARA-C, Idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients. J Exper and Clin Cancer Res 2002;21:481–487.
23. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: Results of the medical research council AML 15 trial. J Clin Oncol 2013;31:3360–3368.
24. Macedo A, Orfao A, Ciudad J, et al. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995;9:1896–1901.
25. Macedo A, Orfao A, Gonzalez M, et al. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: Implications for minimal residual disease studies. Leukemia 1995;9:993–998.
26. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am J Clin Pathol 2009;131:16–26.
27. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European Leukemia Net study. J Clin Oncol 2009;1:5195–5201.
28. Miglino M, Colombo N, Grasso R, et al. Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: Comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. Leuk Lymphoma 2012;53:2214–2217.
29. Baldus CD, Tanner SM, Ruppert AS, et al. BAALC expression predicts clinical outcome of denovo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood 2003;102:1613–1618.
30. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20:1103–1108.
31. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12:1333–1337.
32. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
33. Sanz J, Boluda JC Martín C. Grupo Español De Trasplante Hematopoyético Y Terapia Celular (GETH), et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine, and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012;47:1287–1293.
34. Bacigalupo A, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: An update. Bone Marrow Transplant 2015;50 Suppl 2:S37–S39.
35. Delgado J, Pereira A, Villamor N, et al. Survival analysis in hematologic malignancies: Recommendations for clinicians. Hematologica 2014;99:1410–1440.
36. Russo D, Malagola M, De Vivo A, et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and Idarubicin versus Idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukemia patients. Br J Haematol 2005;131:172–179.
37. Guolo F, Minetto P, Clavio M, et al. Fludarabine containing induction increases minimal residual disease clearance and improves survival in AML patients with concomitant NPM1 and FLT3-ITD mutations. Haematologica 2015;100:386.
38. Candoni A, Martinelli G, Toffoletti E, et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, Idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 2008;32:1800–1808.
39. Feig SA, Krailo MD, Harris RE, et al. Determination of the maximum tolerated dose of Idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: A report from the Childrens Cancer Study Group. Med Pediatr Oncol 1992;20:124–129.
40. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose Idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSG AML201 Study. Blood 2011;117:2358–2365.
41. Clavio M, Cruciani F, Minetto P, et al. De novo AML patients with favorable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and Idarubicin (FLAI): A contribution to the reopened “GO question”. Ann Hematol 2013;92:1309–1318.
42. San Miguel JF, Vidriales MB, López-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to post induction treatment stratification. Blood 2001;98:1746–1751.
43. Schlenk RF. Post-remission therapy for acute myeloid leukemia. Haematologica 2014;99:1663–1670.
44. Krönke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: A study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011;29:2709–2716.
45. Marani C, Clavio M, Grasso R, et al. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. Leuk Res 2013;37:1606–1611.
46. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015;126:319–327.